Carmelo Raffo: How Much Antithrombotic Therapy is Truly Necessary after LAAC?
Carmelo Raffo, Resident Doctor in Cardiovascular Diseases at University of Catania, shared a post on LinkedIn about a recent article he and his colleagues co-authored, published in JAAC Journals, adding:
“How much antithrombotic therapy is truly necessary after LAAC?
And when does it become excessive?
These remain open questions in the antithrombotic management of patients with atrial fibrillation undergoing LAAC.
The paradox is that the procedure is often performed in patients at high bleeding risk or with contraindications to long-term oral anticoagulation.
However, these very patients generally require antithrombotic therapy after device implantation to reduce the risk of device-related thrombosis.
Thus, the challenge is not simply to choose between anticoagulants and antiplatelet agents, but to strike the optimal balance between thrombotic and bleeding risks, tailoring treatment intensity and duration to each patient’s individual risk profile.
In our State-of-the-Art Review, published in JACC, we critically examine the available evidence, current antithrombotic strategies, and the key unresolved questions surrounding antithrombotic management after LAAC.
Thanks to my mentor, Prof. Davide Capodanno, and all my coauthors.”
Title: Antithrombotic Therapy Management After Left Atrial Appendage Closure: Current Regimens, Evolving Evidence, and the Control Group Dilemma
Authors: Carmelo Raffo, Antonio Greco, Kamil Bujak, Nicola Ammirabile, Costanza Bordonaro, Chiara Cosentino, Carmelo Cusmano, Luigi Cutore, Giacinto Di Leo, Simone Finocchiaro, Daniele Giacoppo, Maria Sara Mauro, Placido Maria Mazzone, Francesco Nasisi, Diego Nastasi, Riccardo Prezzavento, Giulia Puglisi, Pietro Redigolo, Paolo Sciacca, Marco Spagnolo, and Davide Capodanno
Stay updated on all scientific advances with Hemostasis Today.
-
Nov 14, 2026, 10:00Benjamin Tur: Putting Iron Deficiency Anemia on the Global Agenda at the Paris Peace Forum’s Child Summit
-
Nov 14, 2026, 09:48Jack Shuang Hou: FDA Approves Bayer’s Sunharbo – First Factor XIa Inhibitor for Secondary Stroke Prevention
-
Nov 14, 2026, 09:42Samwel Mikaye: What Every Patient Should Know About DVT Symptoms and Treatment
-
Nov 14, 2026, 09:37Chronic Preoperative Corticosteroid Use and Postoperative Venous Thromboembolism Risk – Thrombosis and Haemostasis Journal
-
Nov 14, 2026, 09:30Ney Carter Borges: Vulnerable Plaque – Imaging and Clinical Significance
-
Nov 14, 2026, 09:19Mary Cushman: Excellent to Have Jordan Shavit Visit Us for a Virtual Lab Meeting Today
-
Nov 14, 2026, 09:15Chancellor Donald: Heading to ASH 2026 in New Orleans? Let’s Connect on Faculty Opportunities at Tulane
-
Nov 14, 2026, 09:11Sajja Venkatesh: FDA Approved Asundexian, the First Factor XIa Inhibitor
-
Nov 14, 2026, 09:05Selina Evans: How Can Hospitals Make VTE Risk Assessment and Prevention Truly Routine?